GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » ME Therapeutics Holding Inc (XCNQ:METX) » Definitions » Earnings per Share (Diluted)

ME Therapeutics Holding (XCNQ:METX) Earnings per Share (Diluted) : C$-0.30 (TTM As of Feb. 2024)


View and export this data going back to 2023. Start your Free Trial

What is ME Therapeutics Holding Earnings per Share (Diluted)?

ME Therapeutics Holding's Earnings per Share (Diluted) for the three months ended in Feb. 2024 was C$-0.01. Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Feb. 2024 was C$-0.30.

ME Therapeutics Holding's EPS (Basic) for the three months ended in Feb. 2024 was C$-0.01. Its EPS (Basic) for the trailing twelve months (TTM) ended in Feb. 2024 was C$-0.30.

ME Therapeutics Holding's EPS without NRI for the three months ended in Feb. 2024 was C$-0.01. Its EPS without NRI for the trailing twelve months (TTM) ended in Feb. 2024 was C$-0.30.


ME Therapeutics Holding Earnings per Share (Diluted) Historical Data

The historical data trend for ME Therapeutics Holding's Earnings per Share (Diluted) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

ME Therapeutics Holding Earnings per Share (Diluted) Chart

ME Therapeutics Holding Annual Data
Trend Aug22 Aug23
Earnings per Share (Diluted)
-0.01 -0.28

ME Therapeutics Holding Quarterly Data
Aug22 Dec22 May23 Aug23 Nov23 Feb24
Earnings per Share (Diluted) Get a 7-Day Free Trial - -0.15 -0.13 -0.01 -0.01

Competitive Comparison of ME Therapeutics Holding's Earnings per Share (Diluted)

For the Biotechnology subindustry, ME Therapeutics Holding's PE Ratio, along with its competitors' market caps and PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


ME Therapeutics Holding's PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, ME Therapeutics Holding's PE Ratio distribution charts can be found below:

* The bar in red indicates where ME Therapeutics Holding's PE Ratio falls into.



ME Therapeutics Holding Earnings per Share (Diluted) Calculation

Earnings Per Share (EPS) is the amount of earnings per outstanding share of the company's stock. In calculating earnings per share, the dividends of preferred stocks need to subtracted from the total net income first.

ME Therapeutics Holding's Earnings Per Share (Diluted) for the fiscal year that ended in Aug. 2023 is calculated as

Diluted Earnings Per Share (A: Aug. 2023 ) = (Net Income - Preferred Dividends) / Shares Outstanding (Diluted Average)
=(-6.52-0)/23.561
=-0.28

ME Therapeutics Holding's Earnings Per Share (Diluted) for the quarter that ended in Feb. 2024 is calculated as

Diluted Earnings Per Share (Q: Feb. 2024 )=(Net Income - Preferred Dividends / Shares Outstanding (Diluted Average)
=(-0.143-0)/23.589
=-0.01

Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Feb. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was C$-0.30

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Companies also reported diluted shares in their financial reports. Diluted shares include the shares of convertibles or warrants outstanding.


ME Therapeutics Holding  (XCNQ:METX) Earnings per Share (Diluted) Explanation

Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.


Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.


ME Therapeutics Holding Earnings per Share (Diluted) Related Terms

Thank you for viewing the detailed overview of ME Therapeutics Holding's Earnings per Share (Diluted) provided by GuruFocus.com. Please click on the following links to see related term pages.


ME Therapeutics Holding (XCNQ:METX) Business Description

Comparable Companies
Traded in Other Exchanges
Address
177 Robson Street, Vancouver, BC, CAN, V6B 0N3
ME Therapeutics Holding Inc operates its business through ME Therapeutics. It is a preclinical-stage biotechnology company working on novel cancer-fighting drugs in the field of Immuno-Oncology (IO). It is developing preclinical data for its myeloid-targeted candidate assets using validated cancer models.

ME Therapeutics Holding (XCNQ:METX) Headlines

No Headlines